Preliminary Financial Results for the financial year ending 30 June 2017

Maiden results – a year of key milestones successfully achieved

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce its preliminary results for the year ended 30 June 2017.

FY 17 Operational Highlights

  • Successful listing on AIM in December 2016
  • Raised approximately £20 million (before expenses)
  • First in human study data successfully completed
  • Demonstrated safety and efficacy of the application of microwave energy to coagulate bleeds in the colon in 30 patients
  • Represents first device to use microwave energy in combination with radiofrequency
  • CROMA Platform and Speedboat RS2 device received CE Mark approval for microwave energy, adding to the devices previously awarded CE Mark for radiofrequency
  • First patient treated with Speedboat RS2 device using the CROMA platform
  • Non Clinical study pathway agreed with FDA for ablation products at FDA pre-submission meeting
  • Participation in the Semiconductor-based Ultrawideband Micromanipulation of Cancer Stem Cells (“SUMCASTEC”), a Horizon 2020 project

FY 17 Financial Highlights

  • Cash and cash equivalents of £13.7m at 30 June 2017 (as at 30 June 2016: £0.8m)
  • Operating loss after one-off IPO related expenses of £8.9m (4 months to 30 June 2016: £1.9m) reflecting increased operating expenses incurred in relation to clinical and developmental activities as well as further investment in headcount and business infrastructure
  • Cash burn and operating loss in line with management expectations
  • Net assets of £14.7m (as at 30 June 2016: £1.6m)
  • Loss per share of 13 pence (4 months to 30 June 2016: 5 pence)

Post-Period Highlights

  • 510(k) Clearance received ahead of expectations from the US Food and Drug Administration for Creo’s Speedboat RS2 device and CROMA platform
  • Moved into a new facility in Chepstow, providing the engineering development capability and manufacturing capacity to expand and build the business

Craig Gulliford, Chief Executive Officer, commented:

I am delighted to announce our first full year results since listing. The £20 million raised on IPO has enabled us to develop our technology and provide the Company with the resources for future development and commercialisation. Over the last year, we have made significant clinical and regulatory progress advancing us along the pathway to become a leading advanced energy, minimally invasive, medical device company. We continue to execute against our strategy and are on track with our soft launch of Speedboat RS2, the first product in our CROMA platform.

Posted 11/14/17

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read

01 November 2023

Speedboat® UltraSlim: US FDA Clearance

Read

25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months

Read

12 September 2023

Half Year Report: H1-2023

Read

19 June 2023

Speedboat Inject cleared for upper GI use in Europe

Read

01 June 2023

Speedboat™ Inject selected by NICE for assessment

Read